When treated with the DGKα-specific inhibitors Amb639752 or CU-3, together with a low dose of trametinib, significant decreases in tumour size were also observed (Fig. S6C-F), indicating that Dgk is the relevant target of ritanserin cooperating with trametinib in inhibiting Ras-driven polarity-impaired tumour growth. Here, DGKA is linked to neoplasm.